Details for Patent: 10,781,218
Which drugs does patent 10,781,218 protect, and when does it expire?
Patent 10,781,218 protects KOMZIFTI and is included in one NDA.
This patent has forty-five patent family members in thirty-three countries.
Summary for Patent: 10,781,218
| Title: | Substituted inhibitors of menin-MLL and methods of use |
| Abstract: | The present disclosure provides compounds of Formula (II-A), which inhibit the interaction of menin with one or more of MLL1, MLL2 and MLL-fusion oncoproteins. Also disclosed are methods for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. |
| Inventor(s): | Tao Wu, Liansheng Li, Yi Wang, Pingda Ren, Jolanta Grembecka, Tomasz Cierpicki, Szymon Klossowski, Jonathan Pollock, Dmitry Borkin |
| Assignee: | Wellspring Biosciences LLC , University of Michigan System , Kura Oncology Inc |
| Application Number: | US16/082,649 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
| Patent landscape, scope, and claims: | United States Patent 10,781,218: Scope, Claim Breadth, and US Patent Landscape AnalysisExecutive summary: US Patent 10,781,218 claims a broad structural class of drug-like compounds defined by Formula (II-A) with wide latitude across core ring size (C), linker chemotypes (L2, L3), and multi-site substitution (R50, R51, R52, R53/R54, R56, RA/RB/RC), plus dependent claims that carve out specific subsets (e.g., heterocycles, saturation, and selected substituent sets). The independent claim’s drafting strategy is to capture numerous “implementation variants” (different ring/linker/surface chemistries) while maintaining a single umbrella structure. That breadth typically translates into high infringement surface area for later entrants that land anywhere inside the Formula (II-A) parameter space, but it also increases the risk that the claims are vulnerable to invalidity attacks if the specification is thin on exemplars across the full genus or if key limiting features are not supported. What does US Patent 10,781,218 claim and how broad is Formula (II-A)?Featured-snippet answer: The patent claims a genus: “A compound of Formula (II-A) (or salt)” where core (C) spans carbocycles and heterocycles, linkers (L2, L3) span many bond and functional connector types, and multiple substitution variables (R50, RA/RB/RC, R56, R59) permit extensive chemical diversity, with only a few explicit carve-outs (e.g., an exception when R56 = —CH3). 1) Independent claim architecture (Claim 1)Claim 1 is structured around:
2) Practical breadth assessmentFrom a freedom-to-operate perspective, Claim 1 is not a single scaffold with minor edits. It is closer to a parameterized combinatorial genus:
Which dependent claims narrow the genus and what subsets do they target?H2: Which dependent claims narrow US 10,781,218 to specific ring/linker/substitution subsets?Featured-snippet answer: Dependent claims add specific restrictions on:
Key narrowing points by claim number
What parts of the independent claim drive infringement risk?H2: Which claim elements create the largest infringement surface area under US 10,781,218?Featured-snippet answer: The infringement surface area is driven by the independent claim’s “open-ended” definitions of C (ring size), L2 (linker chemotypes), L3 substitution (R56 with optional bonding to ring C), and the substituent sets (R50/R51/R52/R53/R54/R59). Dependent claims narrow those freedoms but do not eliminate the base coverage. 1) C (3–12 carbocycles/heterocycles)A wide C definition means an accused compound does not need an exact core identity. It needs only to land within:
That supports broad coverage against structurally varied analogs. 2) L2 linker is highly permissiveL2 includes:
Any generic design that keeps the backbone but swaps linker chemistry is still likely to fall within Claim 1. 3) L3 and R56 are the key “diversification valve”
4) R50/R51/R56 substitution alphabets are largeThe definitions permit:
That is a common signature of a genus claim intended to cover multiple medicinal-chemistry “series” under one umbrella. What patent landscape questions matter for this patent specifically?H2: How many other US patents typically cover the same compound class as 10,781,218?Featured-snippet answer: The prompt provides only the claim set and does not include bibliographic data (inventor, assignee, application number, filing/priority dates, specification title, or listed related patents). Without those, the number of related US continuations, divisional claims, and overlapping family members cannot be determined from the provided material. H2: What patent expiration dates apply to US 10,781,218 and its family?Featured-snippet answer: Expiration dates depend on priority and filing timeline under 35 USC 154, plus any PTA adjustments and terminal disclaimers. Those dates are not provided in the prompt and cannot be derived from claim text alone. H2: What is the Orange Book status of US 10,781,218?Featured-snippet answer: Orange Book listing requires the drug name/NDA/BLA, which is not included in the prompt. Claim scope alone does not map to Orange Book status. H2: Which companies are challenging patents like 10,781,218 through Paragraph IV?Featured-snippet answer: Paragraph IV challenges are tied to specific ANDA products and listed patents. The prompt includes no NDA/ANDA/BLA identifiers or litigation captions. How strong is the patent estate implied by the claim drafting?H2: How strong is the patent estate for the Formula (II-A) compound class?Featured-snippet answer: Claim strength based on drafting alone is mixed: breadth is high (genus capture), but the enforceability of such breadth hinges on whether the specification supports the full parameter space with disclosure across the “alphabet” of functional groups, linker variants, and core chemotypes. The claim includes many alternatives, creating a typical enablement and written description pressure point. 1) Written description and enablement pressure pointsHigh genuses with:
often increase the challenge that the patent must show possession and enablement for substantially all covered combinations. 2) Litigation leverage pointsFrom a litigation/infringement standpoint, the independent claim’s parameterized language is favorable for plaintiff-side claim construction because it provides:
From a defense standpoint, the same language can enable a narrowing construction argument by emphasizing that certain alternatives require specific internal relationships not captured in the accused compound. What generic entry risks exist under this claim scope?H2: What generic entry risks exist for compounds that differ only by linker or substituent choices?Featured-snippet answer: Risk is elevated for “nearby” analogs because Claim 1 is written to include many substitutions and linker chemotypes. A generic candidate that stays within:
is structurally exposed, even if it uses a different representative functional group choice. 1) Common “design-around” levers and how Claim 1 responds
2) Where design-around may be more plausibleThe largest plausible avoidance vectors (not confirmed without the missing formula structures) would be:
Key Takeaways
FAQs
References
More… ↓ |
Drugs Protected by US Patent 10,781,218
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kura | KOMZIFTI | ziftomenib | CAPSULE;ORAL | 220305-001 | Nov 13, 2025 | RX | Yes | Yes | 10,781,218 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,781,218
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 107891 | ⤷ Start Trial | |||
| Australia | 2017232516 | ⤷ Start Trial | |||
| Brazil | 112018068703 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
